Oxford Professor Turns Immune Discoveries Into Life-Saving Drugs

What if we could learn from the people who survive cancer or resist infection naturally and turn those secrets into medicine for everyone else?

Professor Rachael Bashford-Rogers at Oxford's Lady Margaret Hall is doing exactly that. She's combining cutting-edge immunology with data science to decode how our immune systems protect us and sometimes turn against us.

Her research asks a powerful question: how can the same system that fights off threats also drive diseases like cancer and autoimmune conditions? By studying immune cells in unprecedented detail using massive human datasets, her team is mapping how immunity changes over time and what that means for our health.

But Professor Bashford-Rogers isn't stopping at discovery. She co-founded Alchemab Therapeutics after noticing something remarkable: some people respond exceptionally well to disease. By studying these outliers in detail, her company identifies protective mechanisms that could become treatments for others. Alchemab has grown into a major collaboration with pharmaceutical giant Eli Lilly.

Her newest company, Theraimmune, tackles an area long overlooked by science: how menopause reshapes the immune system and influences disease risk. The goal is to catch problems earlier and intervene more precisely.

The Ripple Effect

This blend of academic research and real-world application is changing how we think about bringing discoveries to patients. Traditional research uncovers important insights, but getting those findings into clinics often requires a different approach entirely.

Oxford's collaborative environment is making this easier. The university now offers students low-risk ways to explore entrepreneurship through internships and innovation networks. Young scientists can test ideas without abandoning their studies.

Professor Bashford-Rogers brings this mindset to her students, encouraging them to think beyond traditional academic careers. She emphasizes curiosity and resilience, reminding them that both research and entrepreneurship involve plenty of failed experiments before the breakthroughs arrive.

Her long-term vision is ambitious: shifting medicine from treating conditions after they appear to understanding and preventing them by targeting underlying biology. It's not just about living longer but staying healthier throughout life.

By identifying what makes some immune systems exceptionally protective, her work offers a blueprint for precision medicine that works with our bodies' natural defenses rather than against them.

The combination of world-class research, industry partnerships, and a culture that supports taking ideas from lab to market is creating an ecosystem where scientific curiosity meets patient impact.